GlassScriptPhysician profile
Tanvir Singh
NPI 1851322168
$2,056.15
in general payments reported to CMS, 2019-2025
22 companies · $22.44 in 2025
The $22.44 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $154 · 2021: $815 · 2022: $241 · 2023: $339 · 2025: $22.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $439.41 | 2019-2023 | Abilify Maintena, Rexulti |
| Sunovion Pharmaceuticals INC. | $328.54 | 2019-2022 | |
| Alkermes, INC. | $244.97 | 2019-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $210.21 | 2019-2022 | |
| Abbvie INC. | $196.41 | 2021-2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.73 | 2021-2023 | |
| Lundbeck LLC | $88.91 | 2019-2022 | |
| Indivior INC. | $58.89 | 2020-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $44.68 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $36.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.31 | 2019-2023 | Uzedy |
| Shire North American Group INC | $26.56 | 2019 | |
| Allergan, INC. | $24.36 | 2019-2020 | |
| Axsome Therapeutics, INC. | $23.88 | 2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $22.59 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $22.44 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $18.62 | 2019 | |
| Bausch Health US, LLC | $18.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.81 | 2019 | |
| Noven Therapeutics, LLC | $16.11 | 2021 | |
| Neurocrine Biosciences, INC. | $15.42 | 2019 | |
| Orexo US, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanvir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.